35
Participants
Start Date
July 18, 2018
Primary Completion Date
October 4, 2021
Study Completion Date
October 4, 2021
Guadecitabine
Guadecitabine
Roswell Park, Buffalo
Temple University, Philadelphia
Duke Cancer Center, Durham
Center for Blood Cancers, Nashville
Ohio State University, Columbus
Ulsan University Hospital, Ulsan
Medizinische Universität Graz, Graz
Rigshospitalet-Copenhagen University Hospital, Copenhagen
Azienda Ospedaliera SS. Antonio E. Biagio E. Cesare Arrigo di Alessandria, Alessandria
Azienda Ospedaliera Universitaria San Martino, Genova
Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan
Azienda Ospedaliero Universitaria S. Maria della Misericordia di Udine, Udine
Hospital Universitario 12 de Octubre, Madrid
Mackay Memorial Hospital, Taipei
National Taiwan University Hospital, Taipei
The Ottawa Hospital - General, Ottawa
Princess Margaret Cancer Center, Toronto
Tokai University Hospital, Isehara-shi
Japanese Red Cross Kyoto Daini Hospital, Kyoto
Saga University Hospital, Saga
Severance Hospital, Yonsei University Health System, Seoul
Lead Sponsor
Astex Pharmaceuticals, Inc.
INDUSTRY